New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 30, 2014
09:13 EDTTWTR, VPRT, HDS, AUXL, SGYP, RFMD, EXC, LL, PNRA, EBAY, POM, ENR, LVLTOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Level 3 (LVLT), up 8%... RF Micro Devices (RFMD), up 6.7%. ALSO HIGHER: Energizer (ENR), up 18% after announcing plan to separate into two publicly traded companies, one focused on Household Products and one on Personal Care... Pepco Holdings (POM), up 18% after Exelon (EXC) to acquire the company for $27.25 per share in cash... Synergy Pharmaceuticals (SGYP), up 5.6% after plecanatide shows positive results in Phase 2B study. DOWN AFTER EARNINGS: Twitter (TWTR), down 11.5%... Lumber Liquidators (LL), down 3%... Panera Bread (PNRA), down 5.6%. ALSO LOWER: eBay (EBAY), down 4.5% after downgraded at Atlantic Equities, price target lowered at JPMorgan after earnings report, company taking $3B charge on repatriation of $9B worth of cash... Auxilium (AUXL), down 14.8% after cutting FY14 revenue view... HD Supply (HDS), down 3% after filing to sell 30M shares of common stock for holders... Vistaprint (VPRT), down 18% after downgraded at Cantor following lower than expected Q3 earnings.
News For TWTR;ENR;POM;EBAY;PNRA;LL;EXC;RFMD;SGYP;AUXL;HDS;VPRT;LVLT From The Last 14 Days
Check below for free stories on TWTR;ENR;POM;EBAY;PNRA;LL;EXC;RFMD;SGYP;AUXL;HDS;VPRT;LVLT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 11, 2014
17:24 EDTSGYPSynergy Pharmaceuticals reports Q2 EPS (28c), consensus (23c)
Subscribe for More Information
16:00 EDTTWTROptions Update; August 11, 2014
iPath S&P 500 VIX Short-Term Futures down 1.33 to 31.90. Option volume leaders: AAPL KMI MNKD PBR AMZN SCTY TWTR TSLA according to Track Data.
13:40 EDTTWTRTwitter sees strong demand in China, hopes to enter market, Nikkei says
Subscribe for More Information
11:04 EDTAUXLActive equity options trading on open
Subscribe for More Information
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
06:09 EDTAUXLAuxilium appoints Andrew Saik as CFO
Subscribe for More Information
August 8, 2014
16:00 EDTTWTROptions Update; August 8, 2014
Subscribe for More Information
12:01 EDTTWTRTwitter revamps its advertising fees to attract more businesses
Subscribe for More Information
10:34 EDTEXCExelon initiated with a Neutral at Tigress Financial
Subscribe for More Information
08:34 EDTAUXLBioSpecifics announces initiation of Phase 2 clinical study of CCH
BioSpecifics (BSTC) announced that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma. The company expects to complete patient enrollment in this trial during the first quarter of 2015. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of CCH for the treatment of lipoma. The primary endpoint of the Phase 2 clinical trial is the reduction in the measureable surface area of the target lipomas, as determined by caliper, at six months post injection. The secondary efficacy endpoints include responders at six months post injection who show a ≥50% decrease in lipoma surface area relative to baseline between CCH and placebo, the change in the length of the target lipoma, the relative change in lipoma surface area as measured by caliper at one month and three months, and the relative change in lipoma volume as measured by MRI. The study will also gather qualitative lipoma characteristics and an assessment of patient satisfaction through a questionnaire administered to each subject prior to injection and at each follow-up visit. BioSpecifics' strategic partner Auxilium (AUXL) has the option to license development and marketing rights to this indication based on a full analysis of the data from this Phase 2 clinical trial, which would transfer responsibility for the future development costs to Auxilium and trigger an opt-in payment and potential future milestone and royalty payments from Auxilium to BioSpecifics.
August 7, 2014
10:20 EDTAUXLHigh option volume stocks
Subscribe for More Information
06:17 EDTAUXLAuxilium backs FY14 revenue guidance of $380M-$420M, consensus $397.45M
Subscribe for More Information
06:16 EDTAUXLAuxilium reports Q2 EPS (44c), consensus (21c)
Subscribe for More Information
05:43 EDTRFMDRF Micro Devices resumed with an Outperform at Pacific Crest
Subscribe for More Information
August 6, 2014
16:01 EDTTWTROptions Update; August 7, 2014
Subscribe for More Information
10:18 EDTTWTRTwitter drifts lower, levels to watch
Subscribe for More Information
09:36 EDTTWTRActive equity options trading on open
Subscribe for More Information
09:02 EDTLVLTLevel 3 added to Commonwealth of Massachusetts' network services contract
Subscribe for More Information
08:26 EDTVPRTVistaprint to host investor day
Subscribe for More Information
06:06 EDTEBAYStubHub launching Music app nationwide, AP reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use